The need to generate new therapies that target P. aeruginosa colonization and infection in chronic wounds has led to promising new avenues being explored including the development of QS inhibitors to disrupt biofilm formation, the use of AMPs as antimicrobials to locally disrupt the bacterial cell membrane, the development of a P. aeruginosa vaccine as well as the use of immunotherapy in the form of—either localized or systemic—MAbs. The gene discussed is ADSL; the disease is infection.